ATF2 and cancer: Interestingly, upregulated OGT activity in cancer cells leads to O-GlcNAcylation on FH-Ser75, competes with AMPK-mediated phosphorylation, compromises FH–ATF2 signaling, and prevents tumor growth arrest (Fig. 4) [72].